BNTX
Income statement / Annual
Last year (2024), BioNTech SE's total revenue was $2.75 B,
a decrease of 27.96% from the previous year.
In 2024, BioNTech SE's net income was -$665.30 M.
See BioNTech SE,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
| Operating Revenue |
$2.75 B |
$3.82 B |
$17.31 B |
$18.98 B |
$482.30 M |
$108.60 M |
$127.58 M |
$61.60 M |
| Cost of Revenue |
$541.30 M
|
$599.80 M
|
$3.00 B
|
$2.91 B
|
$59.30 M
|
$17.40 M
|
$13.69 M
|
$9.32 M
|
| Gross Profit |
$2.21 B
|
$3.22 B
|
$14.32 B
|
$16.07 B
|
$423.00 M
|
$91.20 M
|
$113.89 M
|
$52.28 M
|
| Gross Profit Ratio |
0.8
|
0.84
|
0.83
|
0.85
|
0.88
|
0.84
|
0.89
|
0.85
|
| Research and Development Expenses |
$2.25 B
|
$1.78 B
|
$1.54 B
|
$949.20 M
|
$645.00 M
|
$226.50 M
|
$143.07 M
|
$85.50 M
|
| General & Administrative Expenses |
$531.10 M
|
$495.00 M
|
$481.70 M
|
$276.80 M
|
$95.60 M
|
$42.50 M
|
$24.02 M
|
$22.89 M
|
| Selling & Marketing Expenses |
$67.90 M
|
$62.70 M
|
$59.50 M
|
$50.40 M
|
$12.90 M
|
$800.00 K
|
$3.04 M
|
$6.60 M
|
| Selling, General & Administrative Expenses |
$599.00 M
|
$557.70 M
|
$541.20 M
|
$327.20 M
|
$108.50 M
|
$43.30 M
|
$27.07 M
|
$29.49 M
|
| Other Expenses |
$670.90 M
|
$188.00 M
|
-$405.30 M
|
-$495.00 M
|
-$248.10 M
|
$2.90 M
|
-$2.39 M
|
-$1.43 M
|
| Operating Expenses |
$3.52 B
|
$2.53 B
|
$1.67 B
|
$781.40 M
|
$505.40 M
|
$272.70 M
|
$167.74 M
|
$113.56 M
|
| Cost And Expenses |
$4.07 B
|
$3.13 B
|
$4.67 B
|
$3.69 B
|
$564.70 M
|
$290.10 M
|
$181.43 M
|
$122.88 M
|
| Interest Income |
$0.00
|
$351.31 M
|
$47.37 M
|
$1.56 M
|
$1.46 M
|
$1.76 M
|
$2.06 M
|
$2.06 M
|
| Interest Expense |
$13.16 M
|
$7.76 M
|
$15.82 M
|
$5.63 M
|
$1.86 M
|
$1.69 M
|
$1.78 M
|
$651.44 K
|
| Depreciation & Amortization |
$298.00 M
|
$183.40 M
|
$123.30 M
|
$75.20 M
|
$38.70 M
|
$33.90 M
|
$21.98 M
|
$10.53 M
|
| EBITDA |
-$367.10 M |
$1.38 B |
$13.10 B |
$15.00 B |
-$105.10 M |
-$143.80 M |
-$23.96 M |
-$74.70 M |
| EBITDA Ratio |
-0.13
|
0.36
|
0.76
|
0.79
|
-0.22
|
-1.32
|
-0.19
|
-1.21
|
| Operating Income Ratio |
-0.48
|
0.18
|
0.73
|
0.81
|
-0.17
|
-1.67
|
-0.42
|
-0.99
|
| Total Other Income/Expenses Net |
$636.60 M
|
$495.70 M
|
$311.40 M
|
-$237.40 M
|
-$63.40 M
|
$2.10 M
|
$6.19 M
|
-$24.63 M
|
| Income Before Tax |
-$677.70 M
|
$1.19 B
|
$12.95 B
|
$15.05 B
|
-$145.80 M
|
-$179.40 M
|
-$47.66 M
|
-$85.91 M
|
| Income Before Tax Ratio |
-0.25
|
0.31
|
0.75
|
0.79
|
-0.3
|
-1.65
|
-0.37
|
-1.39
|
| Income Tax Expense |
-$12.40 M
|
$255.80 M
|
$3.52 B
|
$4.75 B
|
-$161.00 M
|
-$200.00 K
|
$600.00 K
|
$45.00 K
|
| Net Income |
-$665.30 M
|
$930.30 M
|
$9.43 B
|
$10.29 B
|
$15.20 M
|
-$179.10 M
|
-$48.02 M
|
-$85.65 M
|
| Net Income Ratio |
-0.24
|
0.24
|
0.55
|
0.54
|
0.03
|
-1.65
|
-0.38
|
-1.39
|
| EPS |
-2.77 |
3.87 |
38.08 |
43.87 |
0.0602 |
-0.85 |
-0.21 |
-0.38 |
| EPS Diluted |
-2.77 |
3.83 |
37.09 |
41.21 |
0.057 |
-0.85 |
-0.21 |
-0.38 |
| Weighted Average Shares Out |
$240.40 M
|
$240.60 M
|
$243.30 M
|
$244.00 M
|
$235.44 M
|
$211.50 M
|
$226.86 M
|
$226.86 M
|
| Weighted Average Shares Out Diluted |
$240.40 M
|
$242.70 M
|
$249.80 M
|
$259.70 M
|
$248.53 M
|
$211.50 M
|
$226.86 M
|
$226.86 M
|
| Link |
|
|
|
|
|
|
|
|
